CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Guideline‐Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient‐Pooled Analysis From the KorHF and KorAHF Registries

Original Research16 Sep 2019

JOURNAL:Circulation. Article Link

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

Nassif ME, Windsor S, DEFINE-HF Investigators. Keywords: SGLT-2 inhibitors; HFrEF; T2DM; Dapagliflozin effect

FULL TEXT PDF